IRIS
SVEGLIATI BARONI, SILVIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.246
EU - Europa 2.155
AS - Asia 889
SA - Sud America 146
AF - Africa 46
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 4
Totale 6.492
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.227
UA - Ucraina 422
IT - Italia 295
SE - Svezia 278
RU - Federazione Russa 245
IE - Irlanda 238
SG - Singapore 233
DE - Germania 226
TR - Turchia 201
CN - Cina 171
HK - Hong Kong 166
DK - Danimarca 155
BR - Brasile 137
FI - Finlandia 104
KR - Corea 85
FR - Francia 84
GB - Regno Unito 61
CI - Costa d'Avorio 23
BE - Belgio 18
MA - Marocco 17
CA - Canada 14
IN - India 12
AT - Austria 11
EU - Europa 6
AU - Australia 4
RS - Serbia 4
AR - Argentina 3
EE - Estonia 3
IQ - Iraq 3
JP - Giappone 3
PK - Pakistan 3
BD - Bangladesh 2
CO - Colombia 2
CZ - Repubblica Ceca 2
EG - Egitto 2
ES - Italia 2
MX - Messico 2
PL - Polonia 2
TN - Tunisia 2
UY - Uruguay 2
VN - Vietnam 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BO - Bolivia 1
DO - Repubblica Dominicana 1
HN - Honduras 1
IL - Israele 1
KZ - Kazakistan 1
LB - Libano 1
LT - Lituania 1
NI - Nicaragua 1
NL - Olanda 1
OM - Oman 1
PH - Filippine 1
RO - Romania 1
SA - Arabia Saudita 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 6.492
Salva come PNG Salva come JPEG
Città #
Chandler 604
Jacksonville 434
Boardman 239
Dublin 235
Fairfield 183
Hong Kong 166
Ashburn 151
Wilmington 136
Singapore 125
New York 121
Lawrence 93
Princeton 93
Centro 87
San Mateo 87
Woodbridge 86
Des Moines 81
Ann Arbor 79
Houston 73
Seattle 58
Moscow 54
Cambridge 49
Beijing 45
The Dalles 39
San Diego 33
Turin 32
Ancona 25
Abidjan 22
Los Angeles 19
Brussels 16
London 15
São Paulo 15
Dallas 14
Guangzhou 14
Helsinki 14
Nuremberg 14
Turku 12
Izmir 11
Marche 11
Shanghai 11
Washington 11
Munich 10
Pune 9
Redmond 8
Wuhan 8
Milan 7
Rio de Janeiro 7
Jesi 6
Jinhua 6
Monte San Pietrangeli 6
Ottawa 6
Vienna 6
Bologna 5
Falls Church 5
San Francisco 5
Auburn Hills 4
Belgrade 4
Belo Horizonte 4
Kilburn 4
Norwalk 4
Santa Clara 4
Southwark 4
Yiwu 4
Betim 3
Brisbane 3
Civitanova Marche 3
Foggia 3
Jiaxing 3
Montreal 3
Osasco 3
Pagani 3
Porto Alegre 3
Quanzhou 3
São Bernardo do Campo 3
Toronto 3
Atlanta 2
Boston 2
Brasília 2
Cairo 2
Casablanca 2
Caxias do Sul 2
Charlotte 2
Chennai 2
Contagem 2
Florence 2
Gessate 2
Hangzhou 2
Hortolândia 2
Jacareí 2
Leawood 2
Montevideo 2
Montréal 2
New Bedfont 2
Nürnberg 2
Olomouc 2
Paris 2
Porto 2
Prescot 2
Rimini 2
Rome 2
Simi Valley 2
Totale 3.821
Salva come PNG Salva come JPEG
Nome #
Induction of Scleroderma Fibrosis in Skin-Humanized Mice by Administration of Anti−Platelet-Derived Growth Factor Receptor Agonistic Autoantibodies 125
Epitope specificity determines pathogenicity and detectability of anti-platelet-derived growth factor receptor α autoantibodies in systemic sclerosis 117
Gut epithelial impairment, microbial translocation and immune system activation in inflammatory bowel disease–associated spondyloarthritis 115
Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease 108
Agonistic anti-PDGF receptor autoantibodies from patients with systemic sclerosis impact human pulmonary artery smooth muscle cells function in vitro 106
Decreased serum levels of the inflammaging marker miR-146a are associated with clinical response to tocilizumab in COVID-19 patients 103
The Exaggerated Collagen Expression in Gvhd-Fibroblasts Is Effectively Inhibited By Therapeutic Concentration of Nilotinib 101
Characterization of binding and quantification of human autoantibodies to PDGFRα using a biosensor-based approach 101
B CELL RECEPTOR EDITING IN SCLERODERMA PATIENTS GENERATES PATHOGENIC ANTI-PDGFR AUTOANTIBODIES 99
Mesenchymal stromal cells from human umbilical cord prevent the development of lung fibrosis in immunocompetent mice 99
Long lasting biological effects of PDGFR agonistic auto-antibodies in scleroderma 96
Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK 1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts 94
c-MYB transactivates the alpha 2(I) collagen gene. 91
Bone formation by distraction clinical and structural studies 91
A reactive Oxygen species -mediated loop mantains increased expression of NADPH oxidases 2 and 4 in skin fibroblasts from patients with systemic sclerosis 87
Characterization of the c-Myb-responsive region and regulation of the human type I collagen α2 chain gene by c-Myb 86
Pathogenic autoantibodies in systemic sclerosis 86
Ha-Ras/ERK1-2 pathway is responsable for oxygen species generation by scleroderma skin fibroblasts 86
ALTERATIONS OF ROS PATHWAYS IN SCLERODERMA BEGIN AT STEM CELL LEVEL 86
Sclerostin and Antisclerostin Antibody Serum Levels Predict the Presence of Axial Spondyloarthritis in Patients with Inflammatory Bowel Disease 85
Isolation of agonistic autoantibodies specific for the PDGF receptor from the B cell repertoire of SSC patients 84
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD 84
Intracellular free radical production by peripheral blood T lymphocytes from patients with systemic sclerosis: Role of NADPH oxidase and ERK1/2 83
WIF1, A WNT PATHWAY INHIBITOR, IS SILENCED IN SYSTEMIC SCLEROSIS BY DNA DAMAGE: A MECHANISM LINKING DNA DAMAGE TO WNT AND FIBROSIS 82
Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab 82
Activation in vitro of scleroderma skin fibroblasts is sustained by increased generation of free radicals through the NADPH-oxidase pathway. 81
Solid monounsaturated diet lowers LDL unsaturation trait and oxidisability in hypercholesterolemic (type IIb) patients 80
Reactive oxygen species are required for maintenance and differentiation of primary lung fibroblasts in idiopathic pulmonary fibrosis 79
Agonistic antibodies in systemic sclerosis 78
Stimulatory autoantibodies against PDGF receptor in systemic sclerosis 76
PDGF receptor as therapeutic and diagnostic target in systemic sclerosis 76
Scleroderma fibroblasts constitutively express the long pentraxin PTX3. 74
AUTOIMMUNITY TO PDGFR: A RELEVANT PATHOGENIC LINK IN SSc 74
Oxidative stress and the pathogenesis of scleroderma: the Murrell's hypothesis revisited. 73
Stimulating autoantibodies to PDGF A/B receptor on sera from scleroderma patients 73
Autoantibodies against the platelet-derived growth factor receptor in scleroderma: comment on the articles by Classen et al and Loizos et al. 73
Cloning of agonistic autoantibodies specific for the PDGF receptor from the B-cell repertoire of SSc patients 73
Scleroderma-like fibrosis in chronic graft-vs-host disease is sustained by anti-PDGF receptors antibodies 71
Coenzyme Q homologs and vitamin E in synaptic and non-synaptic occipital cerebral cortex mitochondria in the ageing rat. 71
Gut microbiota profile in systemic sclerosis patients with and without clinical evidence of gastrointestinal involvemen 71
Stimulatory autoantibodies against PDGF receptors in Scleroderma 70
Circulating miR-320b and miR-483-5p levels are associated with COVID-19 in-hospital mortality 70
Putative functional pathogenic autoantibodies in systemic sclerosis 69
Development of a Skin-Humanized Model as a Novel Tool to Investigate the Pathogenesis of Scleroderma 68
Stimulatory Auto-Antibodies To The PDGF Receptor As Pathology Marker And Therapeutic Target 68
Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis 68
Metabolomic profile of systemic sclerosis patients 68
Ha-Ras/ERK1-2 pathway is responsible for oxygen species generation in scleroderma fibroblasts 67
Isolation and cloning of stimulatory anti-PDGF receptor auto-antibodies from the immunological repertoire of patients with systemic sclerosis 66
The Wnt signalling inhibitor gene, WIF-1, expression is downregulated in fibroblasts derived from systemic sclerosis patients by a persistent oxidative stress 66
Stimulatory autoantibodies against PDGF receptor in serum from patients with GVHD and scleroderma-like changes 66
The long pentraxin PTX3 is a marker of scleroderma fibroblasts activation 65
Tissue-targeted antifibrotic gene therapy using a transgene driven by the promoter of the human type I collagen gene 65
Dietary restriction affects antioxidant levels in rat liver mitochondria during ageing 63
Dietary restriction affects antioxidant levels in rat liver mitochondria diuring aging 63
CLONING OF AGONISTIC AUTOANTIBODIES SPECIFIC FOR THE PDGF RECEPTOR FROM THE B CELL REPERTOIRE OF PATIENTSAFFECTED BY SYSTEMIC SCLEROSIS 63
Stimulatory autoantibodies to the PDGF receptor in scleroderma (Correspondence) 62
Oxidative stress in scleroderma - Maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway 62
Biological effects of serum immunoglobulins from scleroderma patients on human pulmonary artery smooth muscle cells. Role of NOX4 and ROS 61
Coenzyme Q homologs and Vitamin E in synaptic and non-synaptic occipital cerebral cortex mitochondria in the aging rat 60
Epitopes of the human PDGF receptor able to bind human auto-antibodies, antibodies and uses thereof 60
NADPH oxidase, oxidative stress and fibrosis in systemic sclerosis 60
Reactive oxygen species are required for manteinance and differentiation of primary lung fibroblasts in idiopathic pulmonary fibrosis. 59
The treatment of UCD200 and scleroderma fibroblasts with siRNAs anti-C-MYB blocks type I collagen transcription: Toward a gene therapy of scleroderma 58
Isolation and cloning of stimulatory anti-PDGF receptor auto-antibodies from the immunological repertoire of patients with systemic sclerosis 58
Unbalance between Ha- and Ki-Ras is responsible for scleroderma fibroblast activation 57
Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of free radical generation through the NADPH oxidase complex pathway 56
DETECTION OF STIMULATORY ANTI-PDGF RECEPTOR AUTOANTIBODIES BY BIOASSAYS BASED ON DIFFERENT CELL LINES 56
The important role of molecular analyses to evaluate the efficacy of Rituximab treatment in a patient affected by severe multineuropathy in mixed cryoglobulinemia disease. 54
Stimulatory auto-antibodies to the PDGF receptor in patients with chronic GVHD. 54
Monounsaturated diet lowers LDL oxidisability in type IIb and type IV dyslipidemia without affecting coenzyme Q10 and vitamin E contents 53
Lipid raft colocalization of PDGFR-NADPH complex and receptor integrity are important for the activation of the intracellular signaling by scleroderma IgG in normal human fibroblasts 53
Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets 53
Isolation of agonistic autoantibodies specific for the PDGF receptor from the B cell repertoire of SSC patients 52
H-Ras but not K-Ras is responsible for reactive oxygen species generation by scleroderma skin fibroblasts. 52
New insights into the role of oxidative stress in scleroderma fibrosis. 51
Treatment With Rituximab Reduces Activation Of Scleroderma Dermal Fibroblasts 51
Oxidative DNA damage induces the ATM-mediated transcriptional suppressionof the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis 51
Systemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches 51
Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients 49
PDGF/PDGFR: A Possible Molecular Target in Scleroderma Fibrosis 49
Restricted immunoglobulin repertoire and evolutionary mechanism of PDGFR-autoreactive memory B cells in systemic sclerosis 47
Adeno-associated virus type 5 infection via PDGFRα is associated with Interstitial lung disease in systemic sclerosis and generates composite peptides and epitopes recognized by the agonistic immunoglobulins present in patients with systemic sclerosis 46
Monounsaturated diet lowers LDL oxidisability in type IIb and type IV dyslipidemia without affecting coenzyme Q10 and vitamin E contents 46
Stimulatory autoantibodies against PDGF receptor in serum from patients with GVHD and scleroderma-like changes. 44
STIMULATORY AUTOANTIBODIES AGAINST PDGF RECEPTOR IN A LARGE COHORT OF ITALIAN SCLERODERMA PATIENTS 43
Dietary olive oil affects LDL peroxidability in hypercholesterolemic (IIB) patients 43
Association between TNF-α, cortisol levels, and exposure to PM10 and PM2.5: a pilot study 42
Expression profile and regulation of NOX proteins in Systemic Sclerosis 41
Patients with chronic extensive GvHD produce high levels of stimulatory auto-antibodies to the PDGF receptor: a new pathophysiological pathway of the disease progression 40
Intracellular free radical production by peripheral blood T lymphocytes from patients with Systemic Sclerosis: role of NADPH oxidase and ras 39
Rituximab for the treatment of cutaneous involvement in systemic sclerosis. evidence for a pathogenetic role of B-CELLS 39
Restricted immunoglobulin repertoire and evolutionary mechanism of PDGFR-autoreactive memory B cells in systemic sclerosis 38
Increased expression of the ectoenzyme CD38 in peripheral blood plasmablasts and plasma cells of patients with systemic sclerosis 37
The Wnt signalling inhibitor gene, WIF1, is silenced in fibroblasts derived from Systemic Sclerosis patients: role of oxidative stress 36
Mechanism of action of agonistic PDGFR auto-antibodies isolated from scleroderma patients 34
Screening and Analysis of Possible Drugs Binding to PDGFRα: A Molecular Modeling Study 24
Skin Gene Expression Profiles in Systemic Sclerosis: From Clinical Stratification to Precision Medicine 24
Totale 6.610
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.517
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.517
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020139 0 0 0 0 0 0 0 0 0 0 28 111
2020/2021952 45 108 130 3 111 55 99 44 129 67 120 41
2021/2022614 36 169 9 32 11 24 14 56 42 32 51 138
2022/20231.530 134 188 110 161 138 202 6 98 366 9 82 36
2023/2024752 140 29 40 125 127 170 9 12 0 15 6 79
2024/20251.267 149 145 68 12 93 18 174 43 353 103 109 0
Totale 6.610